Cargando…
The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models
Resistance formation of tumors against chemotherapeutics is the major obstacle in clinical cancer therapy. Although low molecular weight heparin (LMWH) is an important component in oncology referring to guideline-based antithrombotic prophylaxis of tumor patients, a potential interference of LMWH wi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154624/ https://www.ncbi.nlm.nih.gov/pubmed/28467373 http://dx.doi.org/10.3390/molecules22050728 |
_version_ | 1783357726966939648 |
---|---|
author | Mueller, Thomas Pfankuchen, Daniel Bastian Wantoch von Rekowski, Kathleen Schlesinger, Martin Reipsch, Franziska Bendas, Gerd |
author_facet | Mueller, Thomas Pfankuchen, Daniel Bastian Wantoch von Rekowski, Kathleen Schlesinger, Martin Reipsch, Franziska Bendas, Gerd |
author_sort | Mueller, Thomas |
collection | PubMed |
description | Resistance formation of tumors against chemotherapeutics is the major obstacle in clinical cancer therapy. Although low molecular weight heparin (LMWH) is an important component in oncology referring to guideline-based antithrombotic prophylaxis of tumor patients, a potential interference of LMWH with chemoresistance is unknown. We have recently shown that LMWH reverses the cisplatin resistance of A2780cis human ovarian cancer cells in vitro. Here we address the question whether this LMWH effect is also valid under in vivo conditions. Therefore, we established tumor xenografts of A2780 and cisplatin resistant A2780cis cells in nude mice and investigated the impact of daily tinzaparin applications (10 mg/kg BW) on anti-tumor activity of cisplatin (6 mg/kg BW, weekly) considering the tumor growth kinetics. Intratumoral platinum accumulation was detected by GF-AAS. Xenografts of A2780 and A2780cis cells strongly differed in cisplatin sensitivity. As an overall consideration, tinzaparin co-treatment affected the response to cisplatin of A2780cis, but not A2780 tumors in the later experimental time range. A subgroup analysis confirmed that initially smaller A2780cis tumors benefit from tinzaparin, but also small A2780 xenografts. Tinzaparin did not affect cisplatin accumulation in A2780cis xenografts, but strongly increased the platinum content in A2780, obviously related to morphological differences in both xenografts. Although we cannot directly confirm a return of A2780cis cisplatin resistance by tinzaparin, as shown in vitro, the present findings give reason to discuss heparin effects on cytostatic drug efficiency for small tumors and warrants further investigation. |
format | Online Article Text |
id | pubmed-6154624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61546242018-11-13 The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models Mueller, Thomas Pfankuchen, Daniel Bastian Wantoch von Rekowski, Kathleen Schlesinger, Martin Reipsch, Franziska Bendas, Gerd Molecules Article Resistance formation of tumors against chemotherapeutics is the major obstacle in clinical cancer therapy. Although low molecular weight heparin (LMWH) is an important component in oncology referring to guideline-based antithrombotic prophylaxis of tumor patients, a potential interference of LMWH with chemoresistance is unknown. We have recently shown that LMWH reverses the cisplatin resistance of A2780cis human ovarian cancer cells in vitro. Here we address the question whether this LMWH effect is also valid under in vivo conditions. Therefore, we established tumor xenografts of A2780 and cisplatin resistant A2780cis cells in nude mice and investigated the impact of daily tinzaparin applications (10 mg/kg BW) on anti-tumor activity of cisplatin (6 mg/kg BW, weekly) considering the tumor growth kinetics. Intratumoral platinum accumulation was detected by GF-AAS. Xenografts of A2780 and A2780cis cells strongly differed in cisplatin sensitivity. As an overall consideration, tinzaparin co-treatment affected the response to cisplatin of A2780cis, but not A2780 tumors in the later experimental time range. A subgroup analysis confirmed that initially smaller A2780cis tumors benefit from tinzaparin, but also small A2780 xenografts. Tinzaparin did not affect cisplatin accumulation in A2780cis xenografts, but strongly increased the platinum content in A2780, obviously related to morphological differences in both xenografts. Although we cannot directly confirm a return of A2780cis cisplatin resistance by tinzaparin, as shown in vitro, the present findings give reason to discuss heparin effects on cytostatic drug efficiency for small tumors and warrants further investigation. MDPI 2017-05-03 /pmc/articles/PMC6154624/ /pubmed/28467373 http://dx.doi.org/10.3390/molecules22050728 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mueller, Thomas Pfankuchen, Daniel Bastian Wantoch von Rekowski, Kathleen Schlesinger, Martin Reipsch, Franziska Bendas, Gerd The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models |
title | The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models |
title_full | The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models |
title_fullStr | The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models |
title_full_unstemmed | The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models |
title_short | The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models |
title_sort | impact of the low molecular weight heparin tinzaparin on the sensitization of cisplatin-resistant ovarian cancers—preclinical in vivo evaluation in xenograft tumor models |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154624/ https://www.ncbi.nlm.nih.gov/pubmed/28467373 http://dx.doi.org/10.3390/molecules22050728 |
work_keys_str_mv | AT muellerthomas theimpactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels AT pfankuchendanielbastian theimpactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels AT wantochvonrekowskikathleen theimpactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels AT schlesingermartin theimpactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels AT reipschfranziska theimpactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels AT bendasgerd theimpactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels AT muellerthomas impactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels AT pfankuchendanielbastian impactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels AT wantochvonrekowskikathleen impactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels AT schlesingermartin impactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels AT reipschfranziska impactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels AT bendasgerd impactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels |